Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo .

Autor: Montes de Oca R; Experimental Medicine Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. maria-del-rocio.x.montes-de-oca-ruiz@gsk.com., Alavi AS; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Vitali N; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Bhattacharya S; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Blackwell C; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Patel K; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Seestaller-Wehr L; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Kaczynski H; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Shi H; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dobrzynski E; Bioanalysis, Immunogenicity and Biomarkers, GlaxoSmithKline, Collegeville, Pennsylvania., Obert L; Translational Medicine and Comparative Pathobiology, GlaxoSmithKline, Collegeville, Pennsylvania., Tsvetkov L; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Cooper DC; Research Statistics, GlaxoSmithKline, Collegeville, Pennsylvania., Jackson H; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Bojczuk P; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Forveille S; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France., Kepp O; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France., Sauvat A; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France., Kroemer G; Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, P.R. China.; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden., Creighton-Gutteridge M; Cell Therapy RU, Oncology R&D, GlaxoSmithKline, Hertfordshire, United Kingdom., Yang J; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Hopson C; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Yanamandra N; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Shelton C; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Mayes P; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Opalinska J; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Barnette M; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Srinivasan R; Experimental Medicine Unit, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Smothers J; Immuno-Oncology and Combinations RU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Hoos A; Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Oct; Vol. 20 (10), pp. 1941-1955. Date of Electronic Publication: 2021 Jul 12.

Alternate Cluster Generation for Picomolar NGS Libraries

Autor: Huerta, G., Heckmann, T., Deiderick, H., Barnette, M., Hunicke-Smith, S.P., Podnar, J.W.

While advancements in library preparation techniques now enable NGS library preparation from single cells and nano- to picograms of DNA or RNA, it can still be difficult to reach Illumina's recommended final library concentration of 2 nM for DNA temp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmc_________::f01bb9c99ee489fa04254e3579974c6f
https://europepmc.org/articles/PMC4162234/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cyclic Nucleotides Increase During Neuronally Induced Relaxation of Sphincteric and Nonsphincteric Gastrointestinal Smooth Muscle.

Autor: Joslyn, A. F., Barnette, M. S., Grous, M., Fudge, M., Price, W. J., Manning, C. D., Thompson, W. E., Barone, F. C., III, H. S. Ormsbee

Publikováno v: Neurogastroenterology & Motility; Mar1990, Vol. 2 Issue 1, p65-72, 8p

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.

Autor: Blackwell C; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., Sherk C; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., Fricko M; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., Ganji G; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., Barnette M; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., Hoang B; Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA., Tunstead J; Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA., Skedzielewski T; Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA., Alsaid H; Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA., Jucker BM; Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA., Minthorn E; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., Kumar R; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA., DeYoung MP; Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA.

Publikováno v: Oncotarget [Oncotarget] 2016 Jun 28; Vol. 7 (26), pp. 39861-39871.